478 656
[(Fig._2)TD$FIG]
Fig. 2 – Overview of studies investigating immune checkpoint inhibitors in selected biomarker-positive patient populations. IC = immune cell;
TC = tumour cell; IHC = immunohistochemistry; ORR = overall response rate.
[(Fig._1)TD$FIG]
4-1BB
CD27
GITR
OX40
4-1BB-L
CD70
GITR-L
OX40-L
PD-L2
PD-L1
Gal-9
CD80/86
PD-L1
PD-1
Tumour cell
Dendritic cell
T cell
MHC II
MHC I
TCR
CTLA-4
TIM3
PD-1
LAG3
PD-1
TCR
Ipilimumab
Tremelimumab
Nivolumab
Pembrolizumab
Nivolumab
Pembrolizumab
Inhibitory
receptors
Co-sƟmulatory
receptors
Atezolizumab
Avelumab
Durvalumab
Atezolizumab
Avelumab
Durvalumab
MOXR0916
PD-L2
Fig. 1 – Schematic overview of co-stimulatory and inhibitory immune checkpoints. Antibodies listed are currently used in urothelial carcinoma trials.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 7 7 – 4 8 1
478